The use of multi-target therapies is not unprecedented in the GBM treatment: for instance, Yang and collegues showed that a triple therapy combining a TCA-cycle inhibitor (small molecule inhibitor “EPIC-0412”), a cytosolic phospholipase A2 inhibitor, and a hexokinase II (HK2)-inhibitor 2-DG, dramatically reduced ATP production (up to 95%), decreased cell proliferation, induced G0/G1 cell cycle arrest, and suppressed tumor growth in vitro and in vivo [35]. The gene discussed is HK2; the disease is neoplasm.